barriers, especially for individuals living in regional and remote areas. 4 Online delivery of psychotherapeutic materials and peer support could overcome many of these barriers and provide widereaching access to those in need.
The majority of online interventions for BD have been based on psychoeducation and cognitive behavioral therapy (CBT), [5] [6] [7] [8] [9] [10] interpersonal and social rhythm therapy 11, 12 and mindfulness. 13 While some have been reported to produce improvements in quality of life 13 and mood severity, 7, 11, 14 many have shown no significant effects. 5, 6, 8, 10 Lauder et al. 7 We present the results of a three-arm, international randomized controlled trial of MoodSwings 2.0. 16 The primary aim was to investigate the comparative efficacies of two intervention arms designed to ameliorate mood symptoms versus an online peer support control between baseline and 3 months, 6 months, 9 months and 12 months. Secondary aims were to examine differences between the intervention arms and control arm on core depressive symptoms, functionality, quality of life, medication adherence and time to episode relapse.
We hypothesized that exposure to the intervention arms would result in decreased symptoms of depression and mania at post-intervention follow-ups in comparison to the peer discussion forum control and that participants assigned to the intervention arms (Groups 2 and 3) would show significant improvement in core depression, functioning, quality of life, and medication adherence, as well as significantly more time to episode relapse.
| ME THODS

| Study design overview
The study was approved by the Institutional Review Board (IRB) at Stanford University (Stanford, CA, USA) and the Human Research Ethics Committee (HREC) at Barwon Health (Deakin University, Geelong, Australia). All participants provided informed consent after receiving detailed information about the study. Participants completed an online, postal or emailed consent form. Participants were randomized using two-site block randomization. After a participant first logged in to the secure section of the site, once the consent process had been completed, they were automatically randomized to level 1, 2, or 3, determining the extent of exposure to site elements. A random numerical sequence was generated by computer and was coded into the program during the development stage. Coded treatments were allocated sequentially to subjects in strict order of their entry into the trial. Research staff were not able to view the randomization code. Participants were randomized to one of three treatment arms.
1.
Discussion forum only (Group 1: control).
2.
Discussion forum plus psychoeducational modules (Group 2).
3. Discussion forum, psychoeducational modules, plus CBT-based interactive tools (Group 3).
Access to the MoodSwings 2.0 website was for 12 months from randomization. All participants had access to a peer discussion forum for the duration of the study period. There was one forum per randomization arm, and discussion posts were screened by a moderator prior to going "live" for participants. Posts containing personal contact information, profanity, or distressing content were edited or deleted. There were five psychoeducational modules delivered bi-weekly followed by four booster modules delivered at 3, 6, 9, and 12 months. The CBT-based tools were delivered in conjunction with the initial five modules, but could only be accessed by Group 3.
A single-blind design was used: clinician-rated assessments were administered by experienced clinical psychologists, trained research staff, and postgraduate psychology students who were blind to treatment assignment. Data analyses were conducted by a blinded biostatistician who was only unblinded after the trial data had been analysed.
| Eligibility
Those aged between 21 and 65 years with a diagnosis of BDI, BDII or BD not elsewhere classified (NEC), as assessed by phone using the Structured Clinical Interview for DSM-5 (SCID-5), 17 were eligible to participate. Participants were required to have local access to emergency care, visit a health care provider at least twice per year for their BD, have access to the internet and a computer, be fluent in English, be competent to provide informed consent, and be willing to provide emergency contact details. Exclusions included those experiencing current mania or psychosis (as assessed via SCID-5) and those currently suicidal (scores ≥3 on the Hamilton Depression Rating Scale
).
| Recruitment
Participants were recruited online from February 2013 to March 2014 through two study sites located in Geelong, Australia and Palo Alto, CA, USA. The study was promoted on social networking websites as well as on health organizations' websites and in newsletters, and using an existing expression of interest list from our previous work. Participants received $40 Amazon e-gift cards for each assessment point completed.
| Outcome measures
Outcome measures were assessed at baseline and at 3, 6, 9, and 12-month follow-up. All outcome measures were collected via telephone interview.
| Primary outcomes
The primary outcomes of depression and mania severity were measured by the Montgomery-Asberg Depression Rating Scale (MADRS) 19 and Young Mania Rating Scale (YMRS). 20 The post-intervention measurements at 12 months of follow-up were considered as the primary comparison for all primary and secondary outcomes. Post-intervention comparisons at 3, 6 and 9 months of follow-up were also reported as a subanalysis.
| Secondary outcomes
Self-report scales delivered online included mental health functioning and physical health functioning assessed by the 12- 
| Participant safety
Participant safety was monitored using predetermined thresholds on the monthly online self-report questionnaires ("red flag assessments") including the MADRS Self-Report (MADRS-S), the Altman and discussion forum posts were screened for suicidal ideation.
A Data Safety and Monitoring Board (DSMB) was established to monitor study progress and to discuss procedural issues, ethical concerns, and participant safety. The DSMB consisted of three psychiatrists and a senior pharmacist independent of the study. The DSMB met with the research team throughout the trial.
Hospitalizations were reported to the DSMB, HREC and IRB within 24 hours as serious adverse events (SAEs). A detailed description of these processes is given elsewhere. 16 
| Statistical analysis
A reduction of 3.5 points on the MADRS was determined to be a meaningful clinical outcome, as it is concordant with antidepressant vs placebo trials. 26 An estimated number of 300 patients (100 per group) was calculated to be needed to detect, with 80% power, a baseline-adjusted between-group mean difference of 3.5 points on the MADRS, assuming a significance level alpha of 0.05, four post assessments, serial autocorrelation equal to 0.4, standard deviation of 10 points and 20% attrition.
The analyses were conducted in accordance with the International Conference on Harmonization E9 statistical principles, 27 and reported according to the consolidated standards of reporting trials recommendations. 28, 29 Intent-to-treat (ITT) analyses were used. All subjects who had a baseline assessment were included. The primary efficacy analyses and all secondary continuous outcomes were based on post-baseline between-group differences; these analyses were conducted using linear mixed- 
| RE SULTS
| Demographics
A total of 1554 people registered interest in the study, 322 provided consent and were screened, and 304 were randomized ( Figure 1 ).
The randomized sample was diverse in demographic characteristics (mean age of 39.5 years, 82% female, 81% from the USA, Australia, Canada or the UK, 55% BDI and 38% BDII; see Table 1 ). There were no significant differences between the three arms on any baseline characteristics.
| Program retention and adherence
Participants had access to their randomized group for 400 days. The 
| Primary outcomes
Results of the LMM analysis for the primary outcomes of depression symptoms (MADRS) and mania (YMRS) are summarized in Table 2 . Considering all post-baseline time points, there was a significant baseline-adjusted difference in levels of depression symptoms for Group 2 (P = .05, χ 2 = 9.38, df = 4) compared to Group 1 (control). Pairwise comparisons revealed significant differences at 3 months (P = .04), 6 months (P < .01), 9 months (P = .05), and 12 months (the primary comparison) (P = .05). There was no significant difference in depression levels for Group 3 (P = .08, χ 2 = 8.47, df = 4) compared to Group 1 (control) (see Figure 2 ). There were also no significant differences for Group 2 (P = .48, χ 2 = 3.49, df = 4) or Group 3 (P = .89, χ 2 = 1.14, df = 4) compared to control in levels of mania (see Figure 3 ).
F I G U R E 1 Consolidated standards of reporting trials diagram of participant flow [Colour figure can be viewed at wileyonlinelibrary.com]
Sensitivity analysis confirmed the primary MADRS finding at 6 months (P = .05) among those deemed symptomatic at baseline (MADRS ≥7) (see Table 3 ).
| Secondary outcomes
Results of the LMM analysis on the secondary outcomes of core depression (MADRS-6 subscale), quality of life (Q-LES-Q), medication adherence (MARS), mental health functioning (SF-12 Mental Health Component Score), and physical health functioning (SF-12 Physical
Health Component Score) are summarized in Table 4 .
With all post-baseline time points considered, there were significant baseline-adjusted differences in levels of core depression across the study for Group 2 (P = .02, χ 2 = 11.20, df = 4) and Group 3 (P = .05, χ 2 = 9.49, df = 4) compared to Group 1 (control). For Group 2, pairwise comparisons revealed a significant difference at 6 months (P < .01) compared to the control. For Group 3, pairwise comparisons revealed a significant difference at 6 months (P = .01) compared to Group 1 (control).
There was a significant difference in levels of physical health functioning for Group 3 (P = .01, χ 2 = 13.6, df = 4) compared to control. Pairwise comparisons showed significant worsening of physical health functioning at 3 months (P < .01) compared to Group 1. There was no significant difference between the control group and Group 2 (P = .51, χ 2 = 3.29, df = 4). Post hoc comparison of Groups 2 and 3 showed a significant difference in physical health functioning at 9 months (P = .01) (see Supporting Information Table S1 ).
No significant differences were found in quality of life, medication adherence, and mental health functioning.
A log-rank test was performed to compare times from baseline (in days) to any occurrence of major mood episode during the follow-up period (TIME). There was no significant effect of treatment group on time from baseline to occurrence any major mood episode during the follow-up period (P = .56).
Regarding satisfaction, in terms of the modules, the second module on "Stress and Triggers" was rated the highest as both most useful and most liked. 
| Subgroup analysis of participants with positive engagement in online interventions
| Completers vs non-completers
Telephone assessments were completed by 304 participants (100%) at baseline, and 157 (52%) at 3 months, 134 (44%) at 6 months, and 141 (46%) at both 9 and 12 months of follow-up. Online self-report assessments were completed by 278 participants (92%) at baseline, and 155 (51%) at 3 months, 131 (43%) at 6 months, 124 (41%) at 9 months, and 92 (30%) at 12 months of follow-up.
Comparisons of those who completed follow-up assessments and those who did not revealed no significant differences in de- 
| Participant safety
Throughout the study, a total of 1372 automated online red flag assessments were completed and 438 (32%) were flagged for scores above thresholds on at least one measure (328 for ASRM mania, 22 for
MADRS-S depression, 112 for MADRS-S suicide, and 57 for HAM-D suicide)
. A further 144 assessments were flagged during quarterly telephone follow-ups (133 for MADRS depression and 21 for YMRS mania), two flags were due to discussion forum posts containing suicidal ideation, and one flag was a result of a private message sent to TA B L E 3 Subgroup sensitivity analysis of primary outcome measures based on minimal symptom cut-offs (<7) on Montgomery-Asberg Depression Rating Scale (MADRS) and Young Mania Rating Scale (YMRS) at baseline Differences in physical health functioning were also demonstrated at 9 months between Groups 2 and 3.
| D ISCUSS I ON
The largest separation between Group 2 and Group 1 in depression and core depression scores, and Group 3 and Group 1 in core depression scores, was seen at the 6-month follow-up point. This finding was also confirmed via sensitivity analysis comparing those deemed symptomatic to those deemed non-symptomatic at baseline -one would not expect those with very low symptom scores at baseline to show meaningful further reductions. This assessment fell 3 months after the release of the final bi-weekly educational module, and coincided with the second booster module. Benefits in depression may be related to the finding that depression literacy (passive information) combined with peer support may help reduce depression. 32 The sensitivity analysis also showed that the intervention had an impact on symptomatic participants rather than just those who were already quite well.
The components of the program appear to have been well uti- shown much larger effect sizes than self-guided programs, highlighting the potential to explore a guided version of the MoodSwings program in future. 35 Nevertheless, there is a need for more research examining whether self-guided interventions may be more cost-effective than guided interventions, offering benefits to users without the added financial burden of additional staff. 36 Additionally, adding "push" engagement elements such as calls, texts and emails has the potential to increase engagement and hence efficacy.
Follow-up rates throughout the study were high for an online mental health intervention, 37 with around 50% completing phone The majority of participants were female, aged around 40 years old, and from the USA, Australia, Canada, and the UK. While most previous studies of online BD programs have utilized single-country samples, it is typical for women in their 40s to be the most common participants. [5] [6] [7] [8] 10 This may be due to gender differences in health information seeking, 38 and age differences related to the delay between onset and diagnosis of BD. 39 Some characteristics of this study limit generalization; these include the high proportion of female participants and lack of ethnic diversity, with the majority of study participants being Caucasian women from the USA, Australia, Canada, or the UK. Of note, this study met the majority of the quality standards proposed by Kiluk et al. 40 for computerassisted therapies for psychiatric disorders and included a randomized controlled design, clinician-measured assessments in addition to selfreport scales, high follow-up rates and a large international sample, differentiating this trial from most past studies. 
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